{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:52:13Z","timestamp":1781869933262,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"KWF Dutch Cancer Society","award":["16159"],"award-info":[{"award-number":["16159"]}]},{"name":"Guangzhou Elite Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-47684-3","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:33:50Z","timestamp":1777041230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thermally enhanced efficacy of chemotherapy potentiates cisplatin-based hyperthermic intraperitoneal chemotherapy in ovarian cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Fan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Reizes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Petra","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten F.","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantijne H.","family":"Mom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Tromp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemien J.","family":"van Driel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas J. A.","family":"Stalpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Crezee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene L.","family":"Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"47684_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong, D. K. et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 19, 191\u2013226 (2021).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"47684_CR2","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.21873\/anticanres.15111","volume":"41","author":"M Friedrich","year":"2021","unstructured":"Friedrich, M., Friedrich, D., Kraft, C. & Rogmans, C. Multimodal treatment of primary advanced ovarian cancer. Anticancer Res. 41, 3253\u20133260 (2021).","journal-title":"Anticancer Res."},{"key":"47684_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.critrevonc.2019.05.014","volume":"140","author":"D Luvero","year":"2019","unstructured":"Luvero, D. et al. Ovarian cancer relapse: From the latest scientific evidence to the best practice. Crit. Rev. Oncol. Hematol. 140, 28\u201338 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"47684_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ygyno.2022.09.005","volume":"167","author":"DM Gershenson","year":"2022","unstructured":"Gershenson, D. M. et al. Contemporary primary treatment of women with stage II\u2013IV low-grade serous ovarian\/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival. Gynecol. Oncol. 167, 139\u2013145 (2022).","journal-title":"Gynecol. Oncol."},{"key":"47684_CR5","first-page":"e27837","volume":"14","author":"A Mohammad","year":"2022","unstructured":"Mohammad, A., Hor, M., Baradeiya, A. M., Qasim, H. & Nasr, M. Is pressurized intraperitoneal aerosolized chemotherapy (PIPAC) effective in ovarian cancer with peritoneal metastasis?. Cureus 14, e27837 (2022).","journal-title":"Cureus"},{"key":"47684_CR6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053\u20131064 (2010).","journal-title":"Am. J. Pathol."},{"key":"47684_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1515\/pp-2023-0019","volume":"9","author":"LF Falla-Zuniga","year":"2024","unstructured":"Falla-Zuniga, L. F. et al. Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC). Pleura Peritoneum 9, 15\u201322 (2024).","journal-title":"Pleura Peritoneum"},{"key":"47684_CR8","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang, C., Xu, C., Gao, X. & Yao, Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics 12, 2115\u20132132 (2022).","journal-title":"Theranostics"},{"key":"47684_CR9","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1021\/mp400345h","volume":"10","author":"N Zhidkov","year":"2013","unstructured":"Zhidkov, N., De Souza, R., Ghassemi, A. H., Allen, C. & Piquette-Miller, M. Continuous intraperitoneal carboplatin delivery for the treatment of late-stage ovarian cancer. Mol. Pharm. 10, 3315\u20133322 (2013).","journal-title":"Mol. Pharm."},{"key":"47684_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/1759-7714.14811","volume":"14","author":"N Mamesaya","year":"2023","unstructured":"Mamesaya, N. et al. Efficacy and safety of carboplatin and etoposide in older extensive-stage small-cell lung cancer patients with a poor performance status. Thorac. Cancer 14, 805\u2013814 (2023).","journal-title":"Thorac. Cancer"},{"key":"47684_CR11","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1007\/s11033-022-07162-1","volume":"49","author":"G Wang","year":"2022","unstructured":"Wang, G., Duan, P., Wei, Z. & Liu, F. Curcumin sensitizes carboplatin treatment in triple negative breast cancer through reactive oxygen species induced DNA repair pathway. Mol. Biol. Rep. 49, 3259\u20133270 (2022).","journal-title":"Mol. Biol. Rep."},{"key":"47684_CR12","doi-asserted-by":"publisher","first-page":"413076","DOI":"10.1155\/2015\/413076","volume":"2015","author":"NC Kampan","year":"2015","unstructured":"Kampan, N. C., Madondo, M. T., McNally, O. M., Quinn, M. & Plebanski, M. Paclitaxel and its evolving role in the management of ovarian cancer. Biomed. Res. Int. 2015, 413076 (2015).","journal-title":"Biomed. Res. Int."},{"issue":"418\u2013420","key":"47684_CR13","first-page":"422","volume":"32","author":"LR Boyd","year":"2018","unstructured":"Boyd, L. R. & Muggia, F. M. Carboplatin\/paclitaxel induction in ovarian cancer: The finer points. Oncology (Williston Park). 32(418\u2013420), 422\u2013414 (2018).","journal-title":"Oncology (Williston Park)."},{"key":"47684_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00280-002-0471-1","volume":"50","author":"R Yamamoto","year":"2002","unstructured":"Yamamoto, R. et al. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer. Cancer Chemother. Pharmacol. 50, 137\u2013142 (2002).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"47684_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel, W. J. et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N. Engl. J. Med. 378, 230\u2013240 (2018).","journal-title":"N Engl J Med."},{"key":"47684_CR16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","volume":"24","author":"SL Aronson","year":"2023","unstructured":"Aronson, S. L. et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): Final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 24, 1109\u20131118 (2023).","journal-title":"Lancet Oncol."},{"key":"47684_CR17","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1200\/JCO.2020.38.15_suppl.6016","volume":"38","author":"O Zivanovic","year":"2020","unstructured":"Zivanovic, O. et al. A randomized phase II trial of secondary cytoreductive surgery (SCS) +\/\u2212 carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with recurrent platinum-sensitive ovarian cancer (EOC). J. Clin. Oncol. 38, 6016\u20136016 (2020).","journal-title":"J. Clin. Oncol."},{"key":"47684_CR18","doi-asserted-by":"publisher","first-page":"100586","DOI":"10.1016\/j.esmoop.2022.100586","volume":"7","author":"P Filis","year":"2022","unstructured":"Filis, P. et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: A systematic review and meta-analysis of randomized trials. ESMO Open 7, 100586 (2022).","journal-title":"ESMO Open"},{"key":"47684_CR19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.jopan.2024.05.016","volume":"39","author":"AM Aljundi","year":"2024","unstructured":"Aljundi, A. M. & Wolfe, R. C. Hyperthermic intraperitoneal chemotherapy. J. Perianesth. Nurs. 39, 688\u2013691 (2024).","journal-title":"J. Perianesth. Nurs."},{"key":"47684_CR20","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.21873\/anticanres.14092","volume":"40","author":"M Friedrich","year":"2020","unstructured":"Friedrich, M., Zinn, W., Kolnsberg, L., Kraft, C. & Kuhn, W. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer: Evaluation of side effects in a single institution cohort. Anticancer Res. 40, 1481\u20131486 (2020).","journal-title":"Anticancer Res."},{"key":"47684_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jviscsurg.2014.07.005","volume":"151","author":"N Bakrin","year":"2014","unstructured":"Bakrin, N. et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J. Visc. Surg. 151, 347\u2013353 (2014).","journal-title":"J. Visc. Surg."},{"key":"47684_CR22","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","volume":"29","author":"CCP Antonio","year":"2022","unstructured":"Antonio, C. C. P. et al. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: A phase 3 clinical trial. Ann. Surg. Oncol. 29, 2617\u20132625 (2022).","journal-title":"Ann. Surg. Oncol."},{"key":"47684_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","volume":"157","author":"MC Lim","year":"2022","unstructured":"Lim, M. C. et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: A randomized clinical trial. JAMA Surg. 157, 374\u2013383 (2022).","journal-title":"JAMA Surg."},{"key":"47684_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13014-015-0462-0","volume":"10","author":"AL Oei","year":"2015","unstructured":"Oei, A. L., Vriend, L. E., Crezee, J., Franken, N. A. & Krawczyk, P. M. Effects of hyperthermia on DNA repair pathways: One treatment to inhibit them all. Radiat. Oncol. 10, 165 (2015).","journal-title":"Radiat. Oncol."},{"key":"47684_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.addr.2020.01.003","volume":"163-164","author":"AL Oei","year":"2020","unstructured":"Oei, A. L. et al. Molecular and biological rationale of hyperthermia as radio- and chemosensitizer. Adv. Drug Deliv. Rev. 163\u2013164, 84\u201397 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"47684_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10238-022-00846-9","volume":"22","author":"CM Liebl","year":"2022","unstructured":"Liebl, C. M., Kutschan, S., D\u00f6rfler, J., K\u00e4smann, L. & H\u00fcbner, J. Systematic review about complementary medical hyperthermia in oncology. Clin. Exp. Med. 22, 519\u2013565 (2022).","journal-title":"Clin. Exp. Med."},{"key":"47684_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N. & Tarsounas, M. Targeting DNA damage response pathways in cancer. Nat. Rev. Cancer. 23, 78\u201394 (2023).","journal-title":"Nat. Rev. Cancer."},{"key":"47684_CR28","doi-asserted-by":"publisher","first-page":"9851","DOI":"10.1073\/pnas.1101053108","volume":"108","author":"PM Krawczyk","year":"2011","unstructured":"Krawczyk, P. M. et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc. Natl. Acad. Sci. USA 108, 9851\u20139856 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"47684_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010097","author":"N van den Tempel","year":"2019","unstructured":"van den Tempel, N. et al. On the mechanism of hyperthermia-induced BRCA2 protein degradation. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers11010097 (2019).","journal-title":"Cancers (Basel)"},{"key":"47684_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01041-x","volume":"23","author":"F Lynce","year":"2021","unstructured":"Lynce, F. & Nunes, R. Role of platinums in triple-negative breast cancer. Curr. Oncol. Rep. 23, 50 (2021).","journal-title":"Curr. Oncol. Rep."},{"key":"47684_CR31","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","volume":"30","author":"S Koole","year":"2020","unstructured":"Koole, S. et al. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int. J. Gynecol. Cancer 30, 888\u2013892 (2020).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"47684_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081775","author":"R Helderman","year":"2020","unstructured":"Helderman, R. et al. The temperature-dependent effectiveness of platinum-based drugs Mitomycin-C and 5-FU during hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer cell lines. Cells https:\/\/doi.org\/10.3390\/cells9081775 (2020).","journal-title":"Cells"},{"key":"47684_CR33","doi-asserted-by":"publisher","first-page":"9826","DOI":"10.3390\/ijms23179826","volume":"23","author":"M Kang","year":"2022","unstructured":"Kang, M., Park, S., Park, S. H., Lee, H. G. & Park, J. H. A double-edged sword: The two faces of PARylation. Int. J. Mol. Sci. 23, 9826 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"47684_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/archotol.128.2.167","volume":"128","author":"SC Coleman","year":"2002","unstructured":"Coleman, S. C. et al. Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: Implications for therapeutic strategies. Arch. Otolaryngol. Head Neck Surg. 128, 167\u2013176 (2002).","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"47684_CR35","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","volume":"140","author":"JP Grabowski","year":"2016","unstructured":"Grabowski, J. P. et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO study group metadatabase. Gynecol. Oncol. 140, 457\u2013462 (2016).","journal-title":"Gynecol. Oncol."},{"key":"47684_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13048-019-0484-6","volume":"12","author":"A Gadducci","year":"2019","unstructured":"Gadducci, A. et al. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J. Ovarian Res. 12, 9 (2019).","journal-title":"J. Ovarian Res."},{"key":"47684_CR37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semcancer.2021.08.011","volume":"77","author":"C Marchetti","year":"2021","unstructured":"Marchetti, C. et al. Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. Semin. Cancer Biol. 77, 144\u2013166 (2021).","journal-title":"Semin. Cancer Biol."},{"key":"47684_CR38","doi-asserted-by":"publisher","first-page":"100945","DOI":"10.1016\/j.gore.2022.100945","volume":"39","author":"RM van Stein","year":"2022","unstructured":"van Stein, R. M. et al. Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus. Gynecol. Oncol. Rep. 39, 100945 (2022).","journal-title":"Gynecol. Oncol. Rep."},{"key":"47684_CR39","doi-asserted-by":"publisher","first-page":"e103988","DOI":"10.1371\/journal.pone.0103988","volume":"9","author":"CM Beaufort","year":"2014","unstructured":"Beaufort, C. M. et al. Ovarian cancer cell line panel (OCCP): Clinical importance of in vitro morphological subtypes. PLoS ONE 9, e103988 (2014).","journal-title":"PLoS ONE"},{"key":"47684_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/02656736.2017.1324642","volume":"34","author":"AL Oei","year":"2018","unstructured":"Oei, A. L. et al. Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i. Int. J. Hyperth. 34, 39\u201348 (2018).","journal-title":"Int. J. Hyperth."},{"key":"47684_CR41","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3109\/02656739009140952","volume":"6","author":"M Urano","year":"1990","unstructured":"Urano, M., Kahn, J. & Kenton, L. A. The effect of cis-diamminedichloroplatinum(II) treatment at elevated temperatures on murine fibrosarcoma, FSa-II. Int. J. Hyperth. 6, 563\u2013570 (1990).","journal-title":"Int. J. Hyperth."},{"key":"47684_CR42","doi-asserted-by":"publisher","first-page":"28116","DOI":"10.18632\/oncotarget.15922","volume":"8","author":"AL Oei","year":"2017","unstructured":"Oei, A. L. et al. Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia. Oncotarget 8, 28116\u201328124 (2017).","journal-title":"Oncotarget"},{"key":"47684_CR43","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1158\/0008-5472.CAN-15-2908","volume":"76","author":"L Schaaf","year":"2016","unstructured":"Schaaf, L. et al. Hyperthermia synergizes with chemotherapy by inhibiting PARP1-dependent DNA replication arrest. Cancer Res. 76, 2868\u20132875 (2016).","journal-title":"Cancer Res."},{"key":"47684_CR44","doi-asserted-by":"publisher","first-page":"629722","DOI":"10.3389\/fimmu.2020.629722","volume":"11","author":"SI Kim","year":"2020","unstructured":"Kim, S. I., Cassella, C. R. & Byrne, K. T. Tumor burden and immunotherapy: Impact on immune infiltration and therapeutic outcomes. Front. Immunol. 11, 629722 (2020).","journal-title":"Front. Immunol."},{"key":"47684_CR45","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1096\/fj.02-1201fje","volume":"17","author":"AV Salnikov","year":"2003","unstructured":"Salnikov, A. V. et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J. 17, 1756\u20131758 (2003).","journal-title":"FASEB J."},{"key":"47684_CR46","doi-asserted-by":"publisher","first-page":"960317","DOI":"10.3389\/fonc.2022.960317","volume":"12","author":"CM Tilsed","year":"2022","unstructured":"Tilsed, C. M., Fisher, S. A., Nowak, A. K., Lake, R. A. & Lesterhuis, W. J. Cancer chemotherapy: Insights into cellular and tumor microenvironmental mechanisms of action. Front. Oncol. 12, 960317 (2022).","journal-title":"Front. Oncol."},{"key":"47684_CR47","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1080\/15384101.2016.1181240","volume":"15","author":"S Yano","year":"2016","unstructured":"Yano, S. et al. Tumor-specific cell-cycle decoy by salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging. Cell Cycle 15, 1715\u20131723 (2016).","journal-title":"Cell Cycle"},{"key":"47684_CR48","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1113\/JP285760","volume":"602","author":"K Watanabe","year":"2024","unstructured":"Watanabe, K. et al. Heat-related changes in the velocity and kinetic energy of flowing blood influence the human heart\u2019s output during hyperthermia. J. Physiol. 602, 2227\u20132251 (2024).","journal-title":"J. Physiol."},{"key":"47684_CR49","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","volume":"39","author":"N Bakrin","year":"2013","unstructured":"Bakrin, N. et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients. Eur. J. Surg. Oncol. 39, 1435\u20131443 (2013).","journal-title":"Eur. J. Surg. Oncol."},{"key":"47684_CR50","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1245\/s10434-014-3599-4","volume":"21","author":"PA Cascales-Campos","year":"2014","unstructured":"Cascales-Campos, P. A. et al. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC\/IV ovarian cancer. Ann. Surg. Oncol. 21, 2383\u20132389 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"47684_CR51","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski, A., He, L., Aittokallio, T. & Tang, J. SynergyFinder: A web application for analyzing drug combination dose-response matrix data. Bioinformatics 33, 2413\u20132415 (2017).","journal-title":"Bioinformatics"},{"key":"47684_CR52","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: An interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739-w743 (2022).","journal-title":"Nucleic Acids Res."},{"key":"47684_CR53","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NA Franken","year":"2006","unstructured":"Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 1, 2315\u20132319 (2006).","journal-title":"Nat. Protoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47684-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47684-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47684-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:11:24Z","timestamp":1781867484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47684-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47684"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47684-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19052"}}